The creation of intravenous solutions, has led the standard practice of using glass for packaging. Having a glass package for parenteral drugs has been tested and studied in the biopharma industry, giving reasoning to why having glass containers are currently the best solution for parenteral packaging. Although, it may seem like the “best” solution as…
Read more
Gilead Issues A Voluntary Nationwide Recall of Two Lots of Remdesivir Due to Presence of Glass Particulates
Glass particles in injectable drugs are extremely dangerous. If a glass particle is injected into a patient, there is no way of removing it. Glass particles that are injected, could reach a blood vessel, travel to various organs and block the blood vessel. Any blocked blood vessel could be fatal, due to blocking of blood…
Read more
Serialization Challenges of Track & Trace in the Biopharma Industry
10% of drugs sold around the world are fake. Counterfeit medicines are the cause of on average 1 million deaths yearly. Increasing of online purchases and disrupted supply chains have intensified and made the risk of counterfeit medicines due to COVID-19. Drugs are “tracked” once after the product has left the manufacturer and landed where…
Read more
Sagent Pharmaceuticals, Inc. Issues Nationwide Recall
November 19, 2021, Sagent Pharma announces a voluntary nationwide recall of Levetiracetam Injection. Four lots of Levetiracetam was recalled due to the lack of a sterile product. Issues pertaining to container closure integrity was brought to attention when found in reserve sample vials. Sagent Pharmaceuticals did not follow USP suggested guidelines for container closure integrity—distributing…
Read more